Skip to main content
. 2019 Jul 29;54(12):2051–2059. doi: 10.1038/s41409-019-0629-7

Fig. 3.

Fig. 3

Survival benefit from two additional cycles of VTD by Revised International Staging System (R-ISS). Patients with R-ISS stage I/II showed superior (a) The 2-year Progression-free survival (PFS) in the VTD6 group (67.8 ± 6.3% vs 90.2 ± 6.9%, P = 0.045). b The 2-year overall survival (OS) rate in these patients was not different. Patients with R-ISS stage III showed similar 2-year PFS (c) and the 2-year OS (d)